Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Status:
Not yet recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

This study is a prospective, single-arm, phase II clinical study for patients with ER+/HER2+ advanced breast cancer.

Phase 2

Fudan University

Fulvestrant
Trastuzumab